UK mid-market firm Lyceum Capital has acquired ClinPharm, a German clinical research company, for its portfolio business Synexus.
This is the third add-on to Synexus since Lyceum acquired it in December 2007 through a de-listing from AIM. It provides fully outsourced clinical trials for global pharmaceutical companies, including patient recruitment and trial management.
The addition of ClinPharm increases Synexus’ presence in mainland Europe with an extra 10 research centres, eight of which are in Germany, and the remainder in Austria and the Ukraine.
Jeremy Hand, managing partner at Lyceum, said: “This is a transformational acquisition for Synexus. Not only does it give the company a major footprint in an area of significant demand, it confirms Synexus’ position as the largest global operator of clinical trials from dedicated sites – a fast growing market.”